PT-141, also known as bremelanotide, is a synthetic analog of alpha-melanocyte stimulating hormone (α-MSH). Unlike PDE5 inhibitors (Viagra, Cialis) that work by increasing blood flow to genital tissue, PT-141 acts centrally — activating melanocortin receptors in the hypothalamus to directly stimulate sexual arousal and desire.

This central mechanism makes PT-141 effective for both men and women, and for cases where the primary issue is low desire rather than physical arousal dysfunction. FDA-approved bremelanotide (Vyleesi) is indicated for hypoactive sexual desire disorder (HSDD) in premenopausal women, but PT-141 is widely used off-label for sexual dysfunction in men as well.

Compounded PT-141 is available at a small fraction of the cost of Vyleesi, typically as a nasal spray for convenience or a SubQ injection for faster onset.

Melanocortin Receptor Agonism
PT-141 binds to MC3R and MC4R receptors in the hypothalamus and limbic system — brain regions governing sexual behavior, reward, and motivation. This triggers dopamine release and activates neural pathways associated with sexual arousal and desire.

Central vs. Peripheral Action
Unlike PDE5 inhibitors that work peripherally on genital blood vessels, PT-141 works centrally on the brain — making it complementary to (and combinable with) PDE5 inhibitors in men with both desire and performance issues.

SubQ injection: 0.5–2mg injected 30–60 minutes before sexual activity

Nasal spray: 1–2 sprays (approx 1mg per spray) 30–45 minutes before activity

Start at the lowest dose (0.5mg) to assess tolerance. Effects last 6–12 hours. Do not use more than once per 24 hours.